AbCellera Biologics will apply its high-throughput single cell antibody platform toward discovering rare monoclonal antibodies with Teva Pharmaceutical Industries. The value of the research collaboration was not disclosed by the companies, which announced the partnership today.

“This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva’s capabilities in novel biologics discovery.”

Teva agreed to pay AbCellera an upfront payment and research payments. AbCellera is also eligible for payments tied to achieving undisclosed milestones associated with the development and approval of therapeutic antibodies.

The collaboration is the second announced by privately held AbCellera with a biopharma giant in less than a week. On Thursday, AbCellera said it would use its platform in a collaboration with Merck & Co. designed to generate antibodies against an undisclosed disease.

AbCellera, based in Vancouver, says its technology is designed to facilitate rapid discovery of monoclonal antibodies directly from natural immune cells. Its platform can identify antibodies with defined properties at a throughput of millions of B cells per run. The technology is designed to screen soluble and complex membrane proteins from humans and other species; tissues that include blood, bone marrow, and spleen; and any B cell.

“Our platform brings important advantages to enable the discovery of rare antibodies with defined specificity and functional activity against difficult membrane protein targets,” said Dr. Carl Hansen, president and CEO of AbCellera.








This site uses Akismet to reduce spam. Learn how your comment data is processed.